论文部分内容阅读
对于世界顶级制药公司来说,依赖重磅炸弹药物推动市场增长的公司正面临压力。辉瑞公司重磅炸弹产品销售前景光明,2002年公司的8个重磅炸弹产品产生了223亿美元的销售额,目前公司已经上市的4个产品也有望到2008年成长为重磅炸弹产品,处于研发管线后期的3个产品届时也有望成为重磅炸弹产品。格兰素、墨克、惠氏和强生等公司都面临重磅炸弹产品的市场份额明显下降的局面。而安进、礼莱和阿斯立康公司的地位在提升。
For the world’s top pharmaceutical companies, companies that depend on blockbuster drugs to drive market growth are under pressure. Pfizer bombshell product sales prospects bright, the company’s eight blockbuster products in 2002 generated a sales of 22.3 billion US dollars, the company has listed four products are also expected to grow to blockbuster products in 2008, at R & D pipeline later three products will also be expected to become blockbuster products. Companies such as Glaxo, Mexico, Wyeth and Johnson & Johnson are facing a clear drop in the market share of blockbuster products. And Amgen, Lilly and Ascolics are on the rise.